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Abstract The Nef protein of HIV-1 is suggested to play a role 
in depletion of uninfected CD4+ T cells leading to the 
development of AIDS. The recombinant soluble Nef protein 
was shown to bind to cell surfaces of various murine lymphoid 
cell lines, including T and B lymphocytes, mastocytoma cells and 
macrophages. Cross-linking of the cell-bound Nef protein with 
anti-Nef antibodies induced apoptotic cytolysis of the cells. 
Although primary lymphocytes from young mice resisted Nef 
binding and Nef-induced cytolysis, treatment of the cells with 
concanavalin A or phytohemagglutinin made them susceptible to 
these activities, indicating that cellular activation is required for 
the apoptosis. The Nef-induced apoptosis also occurred with 
murine cells not expressing CD95 (Fas). These tHidings were 
quite similar to those obtained for human blood cells, suggesting 
that the mouse is applicable for analysis of Nef activities. The 
Nef-induced apoptosis was efficiently suppressed by serine/ 
threonine protein kinase inhibitors, H7, fasudil hydrochloride 
and M3, which did not inhibit CD95 (Fas)-mediated apoptosis. 
On the other hand, bisindolylmaleimide, a protein kinase C 
inhibitor which inhibits CD95 (Fas)-mediated apoptosis, did not 
affect Nef-induced apoptosis. These results suggest that the Nef-
induced apoptosis of murine cells involved a serine/threonine 
protein kinase-dependent signal transduction pathway distinct 
from the CD95 (Fas)-mediated system. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
HIV-1 infection causes serious depletion of CD4+ T cells 
leading to AIDS. Extensive destruction of uninfected T lym-
phocytes occurring in the subclinical stage would be crucial 
for the development of AIDS [1]. In addition to CD4+ T cells, 
CD8+ T cells and neutrophils, which are not infected by HIV-
1, are also destroyed during the course of HIV-1 infection [2-
4]. The Nef protein of HIV-1, found as a soluble form in sera 
of HIV-1-infected patients and also expressed on the surface 
of HIV-1-infected cells, is shown in vitro to bind to uninfected 
CD4+ T cells and, upon cross-linking by anti-Nef antibodies, 
it induces apoptotic cytolysis of the cells [5-7]. We have re-
cently shown that a broad spectrum of human blood cells are 
also susceptible to Nef-induced apoptotic cytolysis, which oc-
curs independently of CD95 (Fas) and requires cellular acti-
vation [8]. These results suggest that the Nef protein is respon-
sible in part for the depletion of uninfected bystander cells. 
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To establish animal models for investigation of Nef protein 
functions, we have examined murine cells for Nef-induced 
apoptotic cytolysis. On the other hand, apoptosis is usually 
mediated by phosphorylation of cellular proteins and a pro-
tein kinase (PK) activity is associated with the Nef protein [9]. 
Therefore, various PK inhibitors were tested for suppression 
of the Nef-induced apoptosis of murine cells. We report here 
that a variety of murine blood cells were destroyed by HIV-1 
Nef in a similar fashion to those observed for human blood 
cells [8], and that the Nef-induced apoptotic cytolysis was 
suppressed by serine/threonine PK inhibitors, H7, fasudil hy-
drochloride and M3 [10-12]. 
2. Materials and methods 
2.1. Soluble Nef protein 
Recombinant soluble Nef proteins derived from the ELI and III-B 
strains of HIV-1 were obtained from Intracel, Cambridge, MA, USA, 
and Immuno Diagnostics Inc., New York, USA, respectively. Bio-
chemical and immunological properties of the proteins were ensured 
by SDS-polyacrylamide gel electrophoresis and Western immunoblot-
ting. 
2.2. Antibodies 
Mouse IgG monoclonal antibodies (mAbs) to the N-terminal region 
of the Nef protein of the BRU and III-B strains were from Advanced 
Biotechnologies Inc., Columbia, NY, USA and Intracel, respectively. 
Hamster IgG mAbs (Jo2 and RK-8) against mouse CD95 (Fas), 
which induce apoptosis of murine cells expressing CD95 (Fas), were 
from PharMingen, San Diego, CA, USA and MBL Co. Ltd., Nagoya, 
Japan, respectively. Rat IgG mAb against mouse Fc receptor was 
from PharMingen. 
2.3. Cells 
Murine cell lines derived from T lymphoma (EL-4), B lymphoma 
(WEHI), myeloma (P3U1 and P3X63Ag), mastocytoma (P815), mac-
rophage (JA-4), and fibroblast (BALB/3T3) were grown in RPMI 
1640 medium supplemented with 10% fetal calf serum (FCS). Lymph 
node lymphocytes were prepared from specific-pathogen-free (SPF), 5-
week-old, male C57BL/6 mice. The primary cells were incubated for 
2 days with 5 ug/ml concanavalin A (ConA) or 1 ug/ml phytohemag-
glutinin (PHA) in the growth medium. 
2.4. Assay of soluble Nef protein bound to cell surfaces 
Fc receptors on cell surfaces were blocked by treatment with anti-
mouse Fc receptor mAb for 20 min at 4°C. Cells were then incubated 
with 1 ug/ml Nef protein for 40 min at 4°C. After washing with cold 
phosphate-buffered saline (pH 7.4, PBS), cells were stained with anti-
Nef(N-terminus) mAb and FITC-conjugated secondary antibody for 
analysis by a flow cytometer (FACScan, Becton Dickinson, San Jose, 
CA, USA) [8]. 
2.5. Analysis of apoptotic cytolysis induced by Nef protein 
A 96-well ELISA plate (ImmunoPlate Maxsorp, Nunc, Glostrup, 
Denmark) was coated with anti-Nef(N-terminus) mAb overnight at 
4°C, and washed with cold PBS. Cell suspension (1 X 105 cells/100 ul 
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Fig. 1. Binding of soluble Nef protein to EL-4 cells and primary lymphocytes of mice. Control cells not treated with Nef (a, b, c) and cells in-
cubated with the soluble Nef protein (ELI strain, 1 ug/ml) for 40 min at 4°C (d, e, f) were treated with both anti-Nef(N-terminus) mAb and 
FITC-conjugated secondary antibody, and analyzed by flow cytometry. EL-4 cells (a, d) and primary lymphocytes from 5-week-old mice after 
incubation for 2 days at 37°C without (b, e) or with 5 ug/ml concanavalin A (c, f). 
RPMI medium containing 10% FCS) was incubated with various 
concentrations of Nef protein for 2 h at 4°C. The cells were washed 
with cold PBS and then incubated with the RPMI medium in the anti-
Nef mAb-coated plate for 24 h at 37°C. Cultured cells were treated 
with the cell lysis solution (0.1% Triton X-100 and 50 ug/ml propi-
dium iodide (PI) in 0.1% sodium citrate) overnight at 4°C [13]. The 
nuclear fraction was analyzed for DNA fragmentation by flow cytom-
etry and pulsed field gel electrophoresis (PFGE) using the Apoptosis 
Ladder Detection Kit (Wako Pure Chemical Industries Ltd., Japan) 
[8]. 
2.6. Analysis of cell surface expression of CD95 (Fas) and CD95 
(Fas)-mediated apoptosis 
Cells (2xl05/well) were incubated with 1 ug/ml anti-mouse CD95 
(Fas) mAb for 30 min at 4°C, stained with FITC-conjugated second-
ary antibody and analyzed by flow cytometry. Cells were also incu-
bated with the mAb for 6 h at 37°C and treated with the cell lysis 
solution for analysis of apoptosis by flow cytometry [8]. 
2.7. Inhibition of Nef-induced apoptosis by PK inhibitors 
A serine/threonine PK inhibitor, HA1077 (hexahydro-l-[5-isoquino-
linesulfonyl]-li/-l,4-diazepine hydrochloride; fasudil hydrochloride, 
Eril), and its metabolite M3 (l-[l-hydroxy-5-isoquinolinesulfonyl]-ho-
mopiperazine) [10-12] were obtained from Asahi Chemical Industry 
Co. Ltd., Osaka, Japan. H-7 (l-[5-isoquinolinylsulfonyl]-2-methylpi-
perazine) and bisindolylmaleimide (BIM), a PKC inhibitor [14], were 
from Sigma Chemical Co., USA. Cells were preincubated with various 
concentrations of the drugs for 30 min at 37°C, and then subjected to 
the assay of Nef-induced apoptosis in the presence of each drug. 
3. Results 
3.1. Binding of HIV-1 Nef protein to murine cells 
We first examined whether the Nef protein of HIV-1 can 
bind to murine cells as well as human blood cells [5,8]. Rep-
resentative results with the EL-4 T cell line and primary 
lymph node lymphocytes from 5-week-old, C57BL/6 mice 
are presented in Fig. 1. The Nef protein (ELI strain) efficiently 
bound to the surface of EL-4 cells, and not to the primary 
lymphocytes. Results obtained for all cell lines tested are sum-
marized in Table 1. The Nef protein of both ELI and III-B 
strains possessed binding activity to a broad spectrum of mur-
ine lymphoid cell lines. On the other hand, the BALB/3T3 
fibroblast line was unsusceptible to Nef. Although primary 
lymph node lymphocytes were negative for Nef binding, about 
60% of the lymphocytes became positive after incubation with 
ConA or PHA (Fig. 1). Together with the knowledge that cell 
line cells were more or less activated, these results suggest that 
cellular activation was required for Nef binding. 
3.2. Apoptotic cytolysis of murine cells by HIV-1 Nef protein 
We have shown that the HIV-1 Nef protein, when cross-
linked by anti-Nef antibodies or immobilized on cell surfaces, 
induces apoptotic cytolysis of uninfected human blood cells 
[5,6,8]. We therefore examined whether uninfected murine 
cells also underwent apoptotic cytolysis by Nef as described 
in Section 2. No smaller DNA fragment was detected with 
control EL-4 cells incubated in the absence of Nef protein. In 
contrast, when EL-4 cells were incubated for 24 h at 37°C 
with the Nef protein (ELI strain), which was cross-linked by 
anti-Nef(N-terminus) mAb, the amount of intact DNA was 
decreased and smaller DNA fragments appeared (Fig. 2A). 
DNA ladder formation was evident in PFGE analysis (Fig. 
Table 1 
Nef binding and Nef-induced apoptosis of murine lymphoid cells 
Cells Nature (origin) Nef binding8 Apoptosis (%)b 
EL-4 
WEHI 
P3U1 
P3X63Ag 
P815 
JA-4 
Balb3T3 
Primary lymphocytes 
T lymphocyte (thymoma) 
B lymphoma (myelomonocytic leukemia) 
B lymphocyte (myeloma) 
B lymphocyte (myeloma) 
Mast cell (mastocytoma) 
Macrophage-like cell (peritoneal macrophage) 
Fibroblast (whole embryo) 
Lymph nodes (normal 5-week-old mouse) 
PHA stimulation0 
ConA stimulation0 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
+ 
77 
54 
68 
83 
60 
45 
< 5 
< 5 
73 
69 
aBinding of soluble Nef protein of the ELI and III-B strains of HIV. +, Positive reaction, 10-fold brighter than control in fluorescence intensity. 
Negative reaction. 
bDNA fragmentaion after 24 h incubation with Nef protein (III-B strain) was quantified against total DNA by FACS analysis. 
"Lymphocytes were incubated with 1 ug/ml of PHA or 5 ug/ml of ConA for 2 days. 
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2B). These were not found when cells were incubated with Nef 
at 4°C. The apoptotic cytolysis depended upon the concentra-
tion of the Nef protein and the incubation period at 37°C 
(Fig. 3). Apoptosis was detected as early as after 6 h of in-
cubation and about 50% of the cells became apoptotic when 
incubated with 30 ng Nef protein per well for 24 h. These 
results indicate that the soluble Nef protein, upon cross-link-
ing by the antibody, directly induced apoptotic cell death in 
the murine cells. Similar results were obtained for the Nef 
protein of the ELI and III-B strains and for all cell lines tested 
that were positive for Nef binding (Table 1). On the other 
hand, BALB/3T3 fibroblast cells and lymph node lymphocytes 
from 5-week-old SPF mice were not killed by the Nef protein. 
However, a proportion of the primary lymphocytes became 
susceptible to Nef-induced apoptotic cytolysis when they were 
activated in vitro with ConA or PHA so that they regained 
Nef binding capacity. 
3.3. Nef-induced apoptotic cytolysis independent of CD95 
(Fas) 
Apoptosis of human CD4+ T cells induced by gpl20 and 
Tat protein of HIV-1 is mediated by CD95 (Fas) [15]. To 
obtain information on whether the Nef-induced apoptosis of 
murine cells depends on the CD95 (Fas) system, we examined 
EL-4 and P3U1 cells for the cell surface expression of CD95 
(Fas). The cells were incubated with the anti-CD95 (Fas) 
mAbs, which induce apoptosis of murine cells expressing 
CD95 (Fas). P3U1 cells were shown to express CD95 (Fas) 
and became apoptotic after incubation with the anti-CD95 
(Fas) mAb (RK-8). On the other hand, neither binding of 
the antibody nor apoptotic cytolysis was found for EL-4 cells 
(data not shown), indicating that CD95 (Fas) was not ex-
Fig. 2. Nef-induced apoptotic cytolysis of EL-4 cells. A: Cell sus-
pension (105 cells/100 ul RPMI 1640 medium with 10% FCS) was 
treated without (a) or with 50 ng/100 ill of soluble Nef (ELI strain) 
(b) for 2 h on ice. The cells were washed and then incubated with-
out Nef for 24 h at 37°C in an ELISA plate coated with anti-
Nef(N-terminus) mAb. The nuclear fractions were stained with PI 
and analyzed by flowcytometry. B: DNA fragmentation analysis by 
PGFE. Lane M, standard 123-bp DNA ladder. Lane 1, control 
cells. Lane 2, Nef-treated cells. 
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Fig. 3. Dose dependence (a) and time course (b) of Nef-induced 
apoptosis of EL-4 cells, a: Cell suspension (105 cells/100 ul) was 
treated with various concentrations of Nef (ELI strain) for 2 h on 
ice, then incubated in the anti-Nef mAb-coated ELISA plate for 24 
h at 37°C and analyzed by flow cytometry. b: Cells were treated 
with Nef at 30 ng/100 ul (•) or 100 ng/100 ul (o) for 2 h on ice, 
then incubated for various periods in the mAb-coated plate and an-
alyzed by flow cytometry. The percentage of DNA fragmentation 
(Ml regions in Fig. 2A) was calculated against total DNA. Each 
plot represents the average of three independent experiments. Bars 
indicate S.D. 
pressed on the cell surface. Therefore, it is concluded that at 
least for EL-4 cells, Nef-induced apoptosis occurred independ-
ently of the CD95 (Fas) system. 
3.4. Inhibition of Nef-induced apoptosis by serinelthreonine 
PK inhibitors 
Since CD95 (Fas)-mediated apoptosis involves phosphoryl-
ation of cellular proteins and a PK activity is associated with 
the HIV-1 Nef protein [9], the Nef-induced apoptosis was also 
expected to depend on PK activities. We therefore examined 
the effect of PK inhibitors on the apoptosis. The Nef-induced 
apoptotic cytolysis of EL-4 and P3U1 cells was efficiently 
suppressed by serine/threonine PK inhibitors, fasudil hydro-
chloride, M3 and H7 (Fig. 4A). The inhibitory effects de-
pended on the concentration of the drugs (Fig. 4B), in parallel 
with the inhibitory effect on PKC enzyme activity in vitro [16]. 
The drugs did not interfere with binding of Nef to the cell 
surface. While H7 was cytotoxic to an extent at a concentra-
tion (0.1 u\M) required for inhibiting the apoptosis, fasudil 
hydrochloride and its metabolite M3 at 3-10 |xM strongly 
inhibited the apoptosis without cytotoxicity. They did not 
affect cell growth at 100 |0.M. Preincubation of the cells with 
the drugs for for at least 30 min was required for the inhib-
ition. 
On the other hand, the Nef-induced apoptosis of EL-4 cells 
was not inhibited by BIM, a PKC inhibitor suppressing CD95 
(Fas)-mediated apoptosis. CD95 (Fas)-mediated apoptosis of 
P3U1 cells induced by the anti-CD95 (Fas) mAb (RK-8) was 
not inhibited at all by fasudil hydrochloride and M3 (data not 
shown). These results also support that the Nef-induced apop-
tosis occurred independently of CD95 (Fas). 
4. Discussion 
The present study demonstrated that the soluble Nef pro-
tein of HIV-1 was able to bind to cell surfaces of a broad 
spectrum of murine lymphoid cells including T and B lym-
phocytes and macrophages, and that cross-linking of the cell-
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Fig. 4. A: Inhibitory effect of PK inhibitors on the Nef-induced 
apoptotic cytolysis of EL-4 cells. Cells were pretreated with PK in-
hibitors for 30 min at 37°C, then incubated with Nef protein, (III-B 
strain, 50 ng/100 ul) in the presence of drugs for 20 h at 37°C, and 
analyzed by flow cytometry. (a) Control cells incubated without 
Nef Nef-treated cells in the absence of PK inhibitor (b), and in the 
presence of 3 U.M fasudil hydrochloride (c), 3 uM M3 (d) and 
0.1 |xM H7 (e). B: Dose dependence of inhibitory effect of fasudil 
hydrochloride (a) and M3 (b) on the Nef-induced apoptosis of EL-4 
cells. Nef at 100 ng/100 ul (□) and 30 ng/100 |xl (•). Each plot rep-
resents the average of three independent experiments. 
bound Nef by anti-Nef antibody induced apoptotic cytolysis 
to the cells. Cellular activation was required for both Nef 
binding and Nef-induced apoptosis. The Nef-mediated apop-
tosis occurred independently of CD95 (Fas). These results 
appear quite similar to those obtained for human blood cells 
[8]. Although mice are insusceptible to HIV-1 infections, the 
present study suggests that the murine model is useful for 
investigating the Nef-induced apoptotic cytolysis of uninfected 
bystander cells [5-8], which may be responsible in part for the 
extensive destruction of a variety of blood cells during the 
course of HIV-1 infection [1-4], and to test drugs inhibiting 
the Nef-mediated apoptosis to prevent the development of 
AIDS. 
The Nef-induced apoptotic cytolysis of murine cells was 
efficiently inhibited by serine/threonine PK inhibitors, fasudil 
hydrochloride, its metabolite M3 [10-12], and H7. These in-
hibitors showed no effect on CD95 (Fas)-mediated apoptosis 
as reported previously [17]. Although a serine/threonine PK 
activity is associated with the Nef protein [9], treatment of the 
Nef protein with the drugs did not affect the binding and 
apoptosis-inducing activities. Pretreatment of the target cells 
with the drugs for more than 30 min was required for the 
inhibition. These results rather suggest that the PK inhibitors 
act on a cellular serine/threonine PK which is involved in an 
apoptosis-inducing signal transduction pathway distinct from 
the CD95 (Fas)-mediated system. The present study also sug-
gests the presence of a Nef-binding protein, which is respon-
sible for the signal transduction, on the surface of various 
murine lymphoid cells as well as human blood cells [8]. To 
identify the molecule, gene cloning is under way. 
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